ATHA Stock Price, Athira Pharma Inc Quote, Chart

Market Summary

USD1.95-0.06

Delayedas of 25 Apr 2024, 10:07 am

-2.99%

ATHA Stock Price

View Fullscreen

ATHA RSI Chart

ATHA Valuation

Market Cap

77.0M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

26.48

Price/Free Cashflow

-0.76

ATHA Price/Sales (Trailing)

ATHA Profitability

Return on Equity

-90.39%

Return on Assets

-73.43%

Free Cashflow Yield

-131.18%

ATHA Fundamentals

ATHA Revenue

Revenue (TTM)

5.2M

ATHA Earnings

Earnings (TTM)

-117.7M

Earnings Growth (Yr)

9.46%

Earnings Growth (Qtr)

17.24%

Breaking Down ATHA Revenue

52 Week Range

1.783.73

(Low)(High)

Last 7 days

-5.2%

Last 30 days

-21.3%

Last 90 days

-35.1%

Trailing 12 Months

-28.1%

How does ATHA drawdown profile look like?

ATHA Financial Health

Current Ratio

5.37

ATHA Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-3.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	9.2M	7.9M	6.5M	5.2M
2021	3.2M	5.1M	7.0M	8.8M
2020	1.0M	0	0	1.3M
2019	0	0	0	754.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Athira Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	worthington mark	sold	-7,018	2.91	-2,412	general counsel
Jan 05, 2024	litton mark james	sold	-14,026	2.91	-4,820	chief executive officer
Jan 05, 2024	lenington rachel	sold	-7,018	2.91	-2,412	coo and cdo
Jan 05, 2024	litton mark james	sold	-14,026	2.91	-4,820	ceo
Jan 05, 2024	lenington rachel	sold	-7,018	2.91	-2,412	chief operating officer
Jan 05, 2024	church kevin	sold	-7,018	2.91	-2,412	chief scientific officer
Jan 05, 2024	worthington mark	sold	-7,018	2.91	-2,412	general counsel
Jan 05, 2024	gengos andrew	sold	-3,515	2.91	-1,208	cfo and chief business officer
Jan 04, 2024	lenington rachel	acquired	-	-	10,000	coo and cdo
Jan 04, 2024	worthington mark	acquired	-	-	10,000	general counsel

Which funds bought or sold ATHA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	BML Capital Management, LLC	reduced	-38.12	-1,068,100	2,466,000	1.65%
Apr 22, 2024	Bristlecone Advisors, LLC	unchanged	-	26,445	233,739	0.02%
Apr 19, 2024	SIMON QUICK ADVISORS, LLC	unchanged	-	6,367	56,274	-%
Apr 18, 2024	Mirador Capital Partners LP	new	-	56,608	56,608	0.01%
Apr 17, 2024	Clarius Group, LLC	unchanged	-	16,601	146,730	0.01%
Apr 09, 2024	American Capital Advisory, LLC	new	-	2,430	2,430	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	425	425	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-2,955	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	696,366	4,127,240	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	added	12.63	3,438,700	13,129,200	0.29%

Are Funds Buying or Selling ATHA?

Are funds buying ATHA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATHA

No. of Funds

Unveiling Athira Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	8.3%	3,153,807	SC 13G
Dec 29, 2023	perceptive advisors llc	14.2%	5,402,964	SC 13D/A
Jul 07, 2023	blackrock inc.	1.8%	669,768	SC 13G/A
Apr 20, 2023	kayne richard a	5.3%	1,983,668	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 01, 2023	blackrock inc.	6.2%	2,363,221	SC 13G/A
Jan 30, 2023	franklin resources inc	0.0%	0	SC 13G/A
Jul 01, 2022	perceptive advisors llc	12.8%	4,811,149	SC 13D/A
Feb 14, 2022	rtw investments, lp	5.1%	1,906,557	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	2.7%	1e+06	SC 13G/A

Recent SEC filings of Athira Pharma Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	3	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 28, 2024	PRE 14A	PRE 14A
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	8-K	Current Report
Feb 22, 2024	S-8	Employee Benefits Plan
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Athira Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Athira Pharma Inc News

Latest updates

Athira Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q1	2019Q4
Revenue	-	-	-	1,227,000	2,959,000	2,596,500	2,234,000	2,336,000	2,079,000	2,589,000	1,831,000	-	-	-
Costs and Expenses	6.3%	31,640,000	29,770,000	32,927,000	24,133,000	23,569,000	23,387,000	18,778,000	17,826,000	16,637,000	10,781,000	9,079,000	1,267,000	-
S&GA Expenses	18.3%	10,025,000	8,477,000	7,691,000	7,168,000	8,766,000	8,927,000	6,160,000	7,119,000	4,613,000	3,336,000	3,892,000	675,000	-
R&D Expenses	1.5%	21,615,000	21,293,000	15,236,000	16,965,000	14,803,000	14,460,000	12,618,000	10,707,000	12,024,000	7,445,000	5,187,000	592,000	-
Net Income	-6.4%	-29,597,000	-27,820,000	-30,135,000	-20,189,000	-24,335,000	-20,980,000	-16,339,000	-15,674,000	-13,974,000	-8,866,000	-7,702,000	-1,805,000	-
Net Income Margin	-5.1%	-20.88	-19.86	-18.53	-12.55	-9.81	-7.25	-6.21	-6.64	-7.68	-8.44	-15.11	-	-
Free Cashflow	8.0%	-24,315,000	-26,435,000	-15,668,000	-21,884,000	-18,741,000	-17,317,000	-19,204,000	-10,427,000	-7,431,000	-7,609,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-13.2%	160	185	208	233	258	274	292	313	332	347	360	369	280	268	-	-	-	-
Current Assets	-13.3%	155	179	192	193	208	229	256	269	261	239	290	312	192	232	-	-	2.00	5.00
Cash Equivalents	-17.9%	91.00	110	114	105	96.00	87.00	95.00	118	111	107	132	128	61.00	166	-	-	2.00	3.00
Net PPE	-6.7%	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	-	-	-	-
Liabilities	0.4%	30.00	30.00	23.00	22.00	23.00	12.00	11.00	11.00	11.00	11.00	9.00	6.00	5.00	8.00	7.00	6.00	5.00	3.00
Current Liabilities	0.8%	29.00	29.00	22.00	20.00	21.00	10.00	10.00	9.00	9.00	9.00	8.00	4.00	4.00	8.00	-	-	1.00	1.00
Shareholder's Equity	-15.9%	130	155	185	211	235	262	281	302	321	336	351	363	274	259	-	-	-	-
Retained Earnings	-9.7%	-309	-281	-248	-219	-191	-161	-141	-116	-95.89	-79.56	-63.88	-49.91	-41.04	-33.34	-	-	-21.09	-15.93
Additional Paid-In Capital	0.5%	440	437	435	432	429	426	424	420	417	416	415	413	315	293	-	-	1.00	1.00
Shares Outstanding	0.3%	38.00	38.00	38.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	36.00	36.00	32.00	-	-	-	-	-
Float	-	-	-	96.00	-	-	-	99.00	-	-	-	328	-	-	461	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-9.6%	-26,293	-23,984	-24,282	-26,194	-15,667	-21,640	-18,590	-16,572	-18,177	-10,299	-7,317	-7,305	-10,665	-9,411	-2,862	-1,175	-	-	-
Share Based Compensation	-10.7%	2,228	2,494	3,119	2,782	2,360	2,420	3,095	2,731	1,435	1,105	1,109	974	415	111	49.00	58.00	-	-	-
Cashflow From Investing	-69.1%	6,391	20,690	32,486	35,522	24,647	13,632	-4,461	23,846	21,373	-14,199	11,455	-22,708	-115,758	-94,313	2.00	1.00	-	-	-
Cashflow From Financing	-	152	-	242	99.00	147	-	297	210	13.00	125	-260	97,211	21,323	184,283	85,304	1,840	-	-	-

ATHA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 93,790	$ 61,464
General and administrative	33,304	32,552
Legal settlement		10,000
Insurance recovery related to legal settlement	(1,628)
Total operating expenses	125,466	104,016
Loss from operations	(125,466)	(104,016)
Grant income	157	5,161
Other income, net	7,637	3,216
Net loss	(117,672)	(95,639)
Unrealized gain (loss) on available-for-sale securities	1,607	(1,568)
Comprehensive loss attributable to common stockholders	$ (116,065)	$ (97,207)
Net loss per share attributable to common stockholders, basic	$ (3.09)	$ (2.53)
Net loss per share attributable to common stockholders, diluted	$ (3.09)	$ (2.53)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	38,020,182	37,733,240
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	38,020,182	37,733,240

ATHA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 90,584	$ 95,966
Short-term investments	56,835	104,378
Unbilled grant receivable		1,227
Prepaid expenses and other current assets	5,682	5,962
Insurance recovery receivable related to legal settlement (Note 7)	1,628
Total current assets	154,729	207,533
Restricted cash	631	420
Property and equipment, net	3,388	4,053
Operating lease right-of-use asset	1,049	1,263
Long-term investments		44,829
Other long-term assets	448	55
Total assets	160,245	258,153
Current liabilities:
Accounts payable	129	2,501
Accrued liabilities	18,343	8,604
Accrued legal settlement (Note 7)	10,000	10,000
Current operating lease liability	368	326
Total current liabilities	28,840	21,431
Operating lease liability, less current portion	1,217	1,585
Total liabilities	30,057	23,016
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 38,172,603 and 37,877,387 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	4	4
Additional paid-in capital	439,739	428,623
Accumulated other comprehensive loss	(349)	(1,956)
Accumulated deficit	(309,206)	(191,534)
Total stockholders' equity	130,188	235,137
Total liabilities and stockholders' equity	$ 160,245	$ 258,153

About Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

CEO	Dr. Mark J. Litton M.B.A., MBA, Ph.D.
WEBSITE	athira.com
INDUSTRY	Biotechnology
EMPLOYEES	63

Athira Pharma Inc Frequently Asked Questions

What is the ticker symbol for Athira Pharma Inc? What does ATHA stand for in stocks?

ATHA is the stock ticker symbol of Athira Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Athira Pharma Inc (ATHA)?

As of Wed Apr 24 2024, market cap of Athira Pharma Inc is 77.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers. The fair value of Athira Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Athira Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATHA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Athira Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether ATHA is over valued or under valued. Whether Athira Pharma Inc is cheap or expensive depends on the assumptions which impact Athira Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATHA.

What is Athira Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ATHA's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 26.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATHA PE ratio will change depending on the future growth rate expectations of investors.